(Q54490269)

30 May 2018

title

Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. (English)

1 reference

30 May 2018

Erb-b2 receptor tyrosine kinase 2

1 reference

1 reference

3

Erinn Downs-Kelly

1 reference

30 May 2018

author name string

Bryce P Portier

1

1 reference

30 May 2018

Zhen Wang

2

1 reference

30 May 2018

Jordi J Rowe

4

1 reference

30 May 2018

Deepa Patil

5

1 reference

30 May 2018

Chis Lanigan

6

1 reference

30 May 2018

G Thomas Budd

7

1 reference

30 May 2018

David G Hicks

8

1 reference

30 May 2018

David L Rimm

9

1 reference

30 May 2018

Raymond R Tubbs

10

1 reference

30 May 2018

publication date

17 August 2012

1 reference

30 May 2018

published in

Modern Pathology

1 reference

30 May 2018

volume

26

1 reference

30 May 2018

issue

1

1 reference

30 May 2018

page(s)

1-9

1 reference

30 May 2018

describes a project that uses

in situ hybridization

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2012.123

inferred from title

exact match

0 references

cites work

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

Fixation time does not affect expression of HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

Fixation time does not affect expression of HER2/neu: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

Delay to formalin fixation effect on breast biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

Current issues in ER and HER2 testing by IHC in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

Fixation time does not affect the expression of estrogen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

HER2 status and benefit from adjuvant trastuzumab in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

Effects of fixative and fixation protocols on assessment of Her-2/neu oncogene amplification status by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

Discrepancy in ER levels of breast carcinoma in biopsy vs mastectomy specimens

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

HER2 testing: how to reach a high concordance rate between immunohistochemistry and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.123

7 January 2021

10.1038/MODPATHOL.2012.123

Identifiers

DOI

1 reference

30 May 2018

Dimensions Publication ID

1030805874

0 references

1 reference

30 May 2018